Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer

NCT05284552 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Epithelial Ovarian Cancer

Interventions

DRUG: Tinzaparin Injectable Solution

Sponsor

University Hospital, Linkoeping

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]